ATG-101 Is a Tetravalent PD-L1×4–1BB Bispecific Antibody That Stimulates Anti-tumor Immunity Through PD-L1 Blockade and PD-L1-Directed 4–1BB Activation

To effectively target 4-1BB and treat diseases resistant to immune checkpoint inhibitors, scientists engineered ATG-101, a tetravalent “2+2” PD-L1×4-1BB bispecific antibody. ATG-101 bound PD-L1 and 4-1BB concurrently, with a greater affinity for PD-L1, and potently activated 4-1BB+ T cells when crosslinked with PD-L1+ cells.